Current Report Filing (8-k)
June 09 2014 - 5:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 9, 2014
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
0-26642 |
|
87-0494517 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code: (801) 584-3600
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN
OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
(b) |
On June 9, 2014, Myriad Genetics, Inc. (Myriad or the Company) announced that James S. Evans, Chief Financial Officer and Treasurer, intends to retire to attend to family health issues.
Mr. Evans will continue to serve as Chief Financial Officer and Treasurer until a replacement is named at a future date. |
ITEM 9.01 |
Financial Statements and Exhibits. |
(d)
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press release dated June 9, 2014 announcing the retirement of James S. Evans as Chief Financial Officer and Treasurer of Myriad Genetics, Inc. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MYRIAD GENETICS, INC. |
|
|
|
|
Date: June 9, 2014 |
|
|
|
By: |
|
/s/ Peter D. Meldrum |
|
|
|
|
|
|
Peter D. Meldrum |
|
|
|
|
|
|
President and Chief Executive Officer |
3
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press release dated June 9, 2014 announcing the retirement of James S. Evans as Chief Financial Officer and Treasurer of Myriad Genetics, Inc. |
4
Exhibit 99.1
News Release
|
|
|
|
|
|
|
Media Contact: |
|
Ron Rogers |
|
Investor Contact: |
|
Scott Gleason |
|
|
(801) 584-3065 |
|
|
|
(801) 584-1143 |
|
|
rrogers@myriad.com |
|
|
|
sgleason@myriad.com |
Myriad Announces Retirement of James Evans, Chief Financial Officer
SALT LAKE CITY, Utah, June 9, 2014 Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that James Evans, chief financial officer of
Myriad, has notified the Company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the Companys CFO until a replacement can be found. Myriad will engage a leading
executive search firm to conduct a national search and will consider both internal and external candidates for the position.
Jim
and I have worked closely together for nineteen years, and he has been a valued member of the Myriad leadership team. Jim has made outstanding contributions during a period of significant growth and transformation for our company, said Peter
D. Meldrum, president and CEO of Myriad. Jim leaves Myriad a stronger company that is well positioned to deliver value to our shareholders long term. He will be missed, and we wish him and his family the very best.
Working at Myriad has been a wonderful experience. I have had the privilege of seeing history in the making as Myriad discovered the
first major genes for a common disease and launched its life-saving test BRACAnalysis. Along the way, I worked with truly outstanding colleagues, said Evans. I leave Myriad with fond memories, and knowing that the Company is
positioned for exceptional growth as its best years still lay ahead.
Evans joined Myriad in 1995 as corporate controller and was
promoted to vice president of Finance in July of 2005. In November of 2007, he was named chief financial officer, a position he has held for the last seven years. He played a major role in driving the execution of Myriads acquisitions of Rules
Based Medicine and Crescendo Biosciences, its international expansion and in designing the Companys capital structure to enhance shareholder returns, including Myriads share repurchase program.
About Myriad Genetics
Myriad Genetics is
a leading molecular diagnostic company dedicated to making a difference in patients lives through the discovery and commercialization of transformative tests to assess a persons risk of developing disease, guide treatment decisions and
assess risk of disease progression and
recurrence. Myriads molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individuals
decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a
difference, please visit the Companys website: www.myriad.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the announced retirement of the Companys CFO; the timing and process for the identification, selection and replacement of the Companys CFO; and the Companys strategic directives under the caption
About Myriad Genetics. These forward-looking statements are managements present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially
and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or
will not continue to increase at historical rates; risks related to changes in the governmental or private insurers reimbursement levels for our tests; the risk that we may be unable to develop or achieve commercial success for additional molecular
diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully
generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services tests and any future tests are terminated or cannot be maintained on satisfactory terms;
risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in
the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses
on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to increased competition and the development of new competing
tests and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our
patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and companion diagnostic services and patents
2
or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new,
changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading Risk Factors contained in Item 1A of our most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the
release, and Myriad undertakes no duty to update this information unless required by law.
###
3
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024